If you took Ozempic, Wegovy, Mounjaro, or Zepbound and a doctor diagnosed you with gastroparesis, you may qualify. Nine MDL law firms are actively taking cases right now.
GLP-1 weight-loss drugs were marketed without warning patients about severe stomach paralysis (gastroparesis). The first cases settled in 2025. The MDL 3094 is consolidated in the Eastern District of Pennsylvania before Judge Pratter. If you have a medical record showing gastroparesis after starting one of these drugs, your claim has real cash value.
The science is specific. A 2023 study in JAMA compared GLP-1 receptor-agonist users with patients taking a different weight-loss drug (bupropion-naltrexone) and found markedly higher rates of pancreatitis (about 9x), bowel obstruction (about 4x), and gastroparesis (about 3.7x) in the GLP-1 group.
The regulatory record followed. In September 2023, the FDA added ileus (intestinal blockage) to the Ozempic prescribing information. In February 2024, the JPML consolidated federal cases into MDL 3094 in the Eastern District of Pennsylvania, covering Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound).
The peer-reviewed study, the regulatory action, and the federal court consolidation underpinning these cases:
Public docket activity in the Eastern District of Pennsylvania.
The MDL covers documented gastrointestinal injuries that appeared after starting a GLP-1 receptor agonist. The strongest claims have imaging or a gastric-emptying study in the record.
The stomach fails to empty properly. Symptoms include chronic nausea, vomiting, early satiety, and abdominal pain. Diagnosed via gastric-emptying study or imaging. Often persists after the drug is stopped.
Tied to relaxer use: Sodhi et al. (JAMA, 2023) found about 3.7x higher gastroparesis rate in GLP-1 users versus a comparator weight-loss drug.
Sudden inflammation of the pancreas. Severe abdominal pain, often requiring hospital admission. Documented via lipase / amylase labs and imaging.
Tied to relaxer use: Same JAMA study found about 9x higher pancreatitis rate in GLP-1 users.
Intestinal blockage that can require hospitalization and sometimes surgery. The FDA added 'ileus' to the Ozempic label in September 2023, confirming the post-market signal.
Tied to relaxer use: Same JAMA study found about 4x higher bowel-obstruction rate in GLP-1 users; FDA's 2023 label update is the regulatory anchor.
Severe persistent vomiting independent of a formal gastroparesis diagnosis. Less consistently accepted but a rising claim type as gastric-emptying-study access has lagged demand.
Tied to relaxer use: Often the symptom profile that drives the gastroparesis workup in the first place.
The MDL covers the GLP-1 receptor agonist class. The two manufacturers and their named products:
All three contain the same active ingredient (semaglutide) at different doses and formulations.
Tirzepatide is a dual GLP-1 + GIP receptor agonist; named in the MDL alongside semaglutide products.
If you took more than one of these drugs across your treatment, you list every product and date range; multiple-product use is the typical case profile.
Two pharmaceutical companies are the named defendants in MDL 3094.
Manufacturer of Ozempic, Wegovy, and Rybelsus. The company has been the dominant supplier of GLP-1 medications globally and has faced parallel investigations and complaints over the speed of label updates relative to known post-market signals.
Named brands: Ozempic, Wegovy, Rybelsus
Manufacturer of Mounjaro and Zepbound (tirzepatide). Tirzepatide is a newer dual GLP-1 + GIP receptor agonist with a similar adverse-event profile to semaglutide-class drugs in early post-market data.
Named brands: Mounjaro, Zepbound
The 60-second eligibility check above tells you if your situation fits the criteria the MDL law firms are intaking. Free, confidential, no obligation.
These are pre-bellwether industry projections tracking MDL 3094. They are not court-ordered amounts. The actual settlement schedule will be set by the first bellwether outcomes (anticipated 2027) and the master settlement negotiations that typically follow.
| Diagnosis or claim type | Projected payout range | What drives the tier |
|---|---|---|
| Wrongful death (severe GI complication) | $1,000,000 to $1,500,000+ | Highest tier. Family of a plaintiff who died of a covered complication. Subject to wrongful-death SOL rules in your state. |
| Severe gastroparesis with repeated hospitalization | $500,000 to $1,000,000 | Documented gastric-emptying study plus multiple hospital admissions, weight loss, malnutrition, or feeding-tube dependency. |
| Acute pancreatitis requiring hospitalization | $300,000 to $500,000 | Documented diagnosis with hospital admission. Tier rises with chronic pancreatitis or pseudocyst complications. |
| Bowel obstruction (ileus) requiring intervention | $200,000 to $500,000 | Higher tier if surgical intervention was required. |
| Documented gastroparesis, outpatient-managed | $150,000 to $300,000 | Standard case profile: gastric-emptying study confirms diagnosis; treatment managed without prolonged hospitalization. |
| Cyclic / chronic vomiting (no formal diagnosis) | $50,000 to $150,000 | Less consistently accepted, but a documented pattern of severe vomiting with relevant medical records can support a claim. |
These are projections, not guarantees. Your attorney will give you a case-specific projection once your records are reviewed.
Four steps. You do almost none of the work after step 1.
Three questions confirm you fit the basic profile: drug taken, diagnosis, and timing. No payment, no commitment.
About 60 seconds.An attorney from the network reviews your answers and reaches out to confirm whether your specific situation fits MDL 3094 intake criteria.
1 to 2 business days.If accepted, the firm gathers your prescription records (proof of GLP-1 use), gastric-emptying study or other imaging (proof of injury), and hospital records. You sign a HIPAA release; the rest is the firm's work.
3 to 6 weeks for record collection.Once records are complete, your case is filed in the MDL. From here, your attorney handles all litigation activity until your case resolves. You can withdraw at any point before signing the final representation agreement.
Filing within 30 days of records being complete.Every state has a statute of limitations (SOL) that sets a hard deadline for filing. Once the clock runs out for your situation, the right to file is gone permanently. The clock varies by state and by when you (or any reasonable person in your shoes) could have connected the injury to the drug.
If you are unsure whether your case is still within the window, file the eligibility check now. The attorney review is free and the SOL question is one of the first things they evaluate. Missing the SOL is permanent.
claimscout is not a law firm. We connect you with attorneys from a vetted network of firms that handle MDL 3094 cases as a core practice area.
claimscout is a referral service. We do not provide legal advice, do not represent you in court, and are not a substitute for an attorney-client relationship. Sponsored attorney advertising. Past results do not guarantee future outcomes.
If you started a GLP-1 drug and your stomach stopped emptying, that's gastroparesis. It's documented on imaging. The law firms in this MDL only want cases with that diagnosis — no diagnosis, no claim.
Real ads, scraped this morning from Meta's public Ad Library. If they are paying to find you, your claim has cash value. We let you pick which firm you want to work with, or skip them entirely and file directly.
Companies have an obligation to make sure that the products they market and sell are safe. Those who have been impacted should act fast. Product liability lawsuits are already pending. We know that you didn’t ask...
“Ozempic use for weight loss is up more than 2,000% — and most people have no idea what they’re risking,” says endocrinologist Dr. Theresa Bell. In this article, she breaks down why so many users experience nausea,...
“Ozempic use for weight loss is up more than 2,000% — and most people have no idea what they’re risking,” says endocrinologist Dr. Theresa Bell. In this article, she breaks down why so many users experience nausea,...
Ozempic, Wegovy, Rybelsus (Novo Nordisk), Mounjaro, and Zepbound (Eli Lilly). If you took any of these and developed a covered GI injury, the eligibility check above is the right next step.
The primary claims are gastroparesis (stomach paralysis), acute pancreatitis, and bowel obstruction (ileus). Cyclic or chronic vomiting can also qualify with the right documentation.
Yes. Filing does not require you to stop the drug. That decision is between you and your doctor. Your attorney will note ongoing use in the case record.
Eventually: proof you took a GLP-1 drug (prescription records, pharmacy printout), proof of the GI injury (gastric-emptying study, imaging, or hospital discharge), and a treatment record. The intake team gathers most of it under HIPAA authorization.
That is common and not disqualifying. The science linking GLP-1 use to gastroparesis is recent (the JAMA study is from October 2023). Many clinicians had not yet made the connection. Your attorney's expert reviewers will evaluate the timeline.
Realistically, 2 to 4 years from filing. Bellwether trials in MDL 3094 are anticipated in 2027, and master settlement negotiations typically follow the first bellwether outcomes.
It is helpful but not strictly required to start. Many plaintiffs have severe symptoms and hospital records but no formal study. The attorney can advise whether to pursue a study as part of intake.
No. The eligibility check above connects qualified cases to an MDL-experienced attorney from the network. You can accept or decline that connection.
That is common as patients switch between GLP-1 drugs. Your case will name both manufacturers; the attorney sorts out which exposure window aligned with the injury onset.
A bellwether is a representative test case chosen from the MDL to be tried first. Outcomes (verdicts or settlements) inform the value of the remaining cases. MDL 3094 bellwether selection is in progress.
Tiered settlement frameworks are typical in mass torts. Tiers are based on injury severity, treatment burden, and exposure duration. The compensation table above shows current pre-bellwether projections.
A multidistrict litigation (MDL) consolidates many similar cases under one judge for pretrial proceedings. MDL 3094 is the consolidation of GLP-1 GI-injury cases in the Eastern District of Pennsylvania. Each plaintiff's case stays individual, but discovery and bellwether trials are coordinated.
Nothing. We get paid by the law firms or affiliate fees from the court-appointed administrator. You pay zero up front and zero out of any payout you receive.
Only if you check the consent box. We give you the choice. If you do not consent, your claim is captured and we route it to the administrator directly without sharing your phone number.
Yes, always. If we route your claim to a law firm, you can choose to file directly with the same firm or pick a different one. We exist because most people throw the notice letter away. We make it not happen.
No. We are not a law firm and do not provide legal advice. We are a platform that captures your claim, qualifies it, and routes it to the court-appointed administrator or a law firm of your choice.